Financings
Aquinox Pharmaceuticals Inc. raised $18 million from a Series C financing.
Chimerix Inc. and Omthera Pharmaceuticals Inc. established terms for their initial public offerings.
Revance Therapeutics Inc. raised $33 million in a Series E financing and converted $71 million in convertible debt into Series E preferred stock.
Taris Biomedical Inc. said it raised an additional $12.5 million in a financing round.
Deals
BIND Therapeutics Inc. is collaborating with Pfizer Inc. on multiple Accurins in small-molecule targeted therapies.
DARA BioSciences Inc. signed a deal with Prime Therapeutics Specialty Pharmacy LLC for distribution of two of its lead products.
Endo Pharmaceuticals Holdings Inc. returned Urocidin, a bladder cancer candidate, to Bioniche Life Sciences Inc.
Ferro Corp. sold its Pfanstiehl Laboratories pharma business, to PLI Holdings Inc. for $16.9 million.
Foundation Medicine Inc. and Agios Pharmaceuticals Inc. signed a multiyear diagnostic partnership.
Ra Pharmaceuticals Inc. and Merck & Co. Inc. will collaborate on development of peptide drugs.
Tetragenetics Inc. signed a licensing agreement with Amgen Inc. for an undisclosed surface antigen.
. . . And More
ArQule Inc. regained rights to compounds covered under its AKT collaboration with Daiichi Sankyo Co. Ltd.
Adenosine Therapeutics LLC engaged Needham & Co. to explore strategic options for Stedivaze, a highly selective adenosine A2A agonist.
ChronTech Pharma AB shares dropped following the failure of its ChronVac-C HCV vaccine
Clavis Pharma AS reported a Phase III failure of elacytarabine in advanced acute myeloid leukemia.
Genmab A/S said the FDA granted fast-track designation for daratumumab for multiple myeloma.
The FDA approved Invokana (canagliflozin) by Janssen Pharmaceuticals Inc. for Type II diabetes.
Oculus Innovative Sciences Inc. disclosed a 1-for-7 reverse split of its common stock (NASDAQ:OCLS).